Halberd Begins Preclinical Testing at Mississippi State University (MSU)

Rhea-AI Summary

Halberd Corporation (OTC PINK:HALB) has initiated preclinical testing of a novel nasal spray aimed at mitigating the adverse effects of Traumatic Brain Injury (TBI) at Mississippi State University (MSU). This study marks a significant milestone as it aims to measure the relationship between head impact severity and brain injury, a first in this field. The nasal spray is designed to inhibit the production of inflammatory cytokines and neurotransmitters following head trauma, potentially improving outcomes when administered shortly after injury. Funded entirely by Epidemiologic Solutions Corporation, the project has 75% of its costs covered and is structured to comply with FDA regulations, paving the way for market approval. The product targets a substantial market gap, with no other treatments addressing TBI prevention in this manner.

Positive

• Initiation of preclinical testing at Mississippi State University for a nasal spray targeting TBI.
• Unique approach to treating TBI by blocking inflammatory cytokines - no current market competition.
• Project fully funded by a nonprofit, minimizing financial risk for Halberd.
• Compliance with FDA regulations through collaboration with mdi Consultants.

Negative

• None.

JACKSON CENTER, PA / ACCESSWIRE / April 11, 2023 / Halberd Corporation (OTC PINK:HALB) has announced that preclinical testing is now underway at Mississippi State University (MSU) for its groundbreaking patent-pending nasal spray designed to suppress the negative effects of Traumatic Brain Injury (TBI). This innovative research involves the development of test mechanisms by MSU's staff to quantify and correlate the level of head impact to the degree of resulting brain injury, which has never been done before. Once these critical parameters are established, actual nasal spray testing will commence.

Halberd's approach to preventing the cascade of negative effects in the brain following head trauma is through the use of a proprietary blend of three active ingredients in a nasal spray, designed to block the excess production of certain identified inflammatory cytokines and neurotransmitters. MSU's pre-clinical tests aim to document the improvement in outcomes after brain injury from the administration of the nasal spray within hours of the traumatic event.

Halberd has previously stated that this project is fully funded by Epidemiologic Solutions Corporation, a 501 (c) (3) non-profit charity, enabling Halberd Corporation to proceed without the need for a partnership with Big Pharma or another partner. In compliance with MSU requirements, 75% of the estimated project costs have already been paid. The company is also working with mdi Consultants to ensure that testing and documentation conform to the FDA's strict requirements on the road to market approval.

The potential market for a product that proactively treats TBI through the suppression of excess neurotransmitters or inflammatory cytokines associated with brain trauma is enormous. Currently, no other product on the market addresses this need. If the test results are positive, this will be a significant step towards realizing Halberd's first therapeutic product, with enormous potential.

To get the latest news on Halberd's exciting developments, subscribe by submitting this.
(https://halberdcorporation.com/contact-us/)

For more information please contact:
William A. Hartman
w.hartman@halberdcorporation.com
support@halberdcorporation.com
www.halberdcorporation.com
Twitter:@HalberdC

About Mississippi State University College of Veterinary Medicine (CVM).
Mississippi State University College of Veterinary Medicine (MSU CVM) was founded in 1974 The CVM has a total of six locations and serves all 82 counties in Mississippi as well as the entire Southeastern United States. The College's main campus is in Starkville and includes the Wise Center, which houses its main teaching hospital, the Animal Health Center. The MSU CVM Department of Comparative Biomedical Sciences faculty and staff represent the basic scientific disciplines required for education of veterinarians. MSU CVM is committed to an ethical approach to treating animals with a genuine passion and drive.

About Halberd Corporation.
Halberd Corporation (OTC PINK:HALB), is a publicly traded company on the OTC Market, and is in full compliance with OTC Market reporting requirements. Since its restructuring in April of 2020, Halberd has obtained exclusive worldwide rights to three issued patents and has filed 22 related provisional, PCT, or utility patent applications to enhance its value to its stockholders and to attract the interests of potential development partners.

Safe Harbor Notice
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). The Company' cautions our readers that statements, and assumptions made in this news release constitute forward-looking statements and makes no guarantee of future performance. Forward-looking statements are based on estimates and opinions of management at the time the statements are made. These statements may address issues that involve significant risks, uncertainties and associated estimates made by management. Actual results could differ materially from current projections or implied results. Halberd Corporation undertakes no obligation to revise these statements following the date of this news release.
(C) 2023, Halberd Corporation

SOURCE: Halberd Corporation

View source version on accesswire.com:
https://www.accesswire.com/748456/Halberd-Begins-Preclinical-Testing-at-Mississippi-State-University-MSU

FAQ

What is Halberd Corporation's latest press release about?

Halberd Corporation announced the start of preclinical testing for a nasal spray aimed at reducing the negative effects of Traumatic Brain Injury (TBI) at Mississippi State University.

What are the unique features of Halberd's TBI nasal spray?

The nasal spray uses a proprietary blend to block excess inflammatory cytokines and neurotransmitters associated with brain trauma.

How is Halberd Corporation funding its TBI nasal spray project?

The project is fully funded by Epidemiologic Solutions Corporation, a non-profit organization.

What is the market potential for Halberd's nasal spray for TBI?

The nasal spray targets a significant market need as currently no products effectively address proactive treatment for TBI.

What percentage of the project's costs have been covered for Halberd's nasal spray testing?

Seventy-five percent of the estimated project costs have already been paid.